Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Credit agrmnt [a]
CC transcript

CORE LABORATORIES N V (CLB) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 SC 13G/A ALGER ASSOCIATES INC reports a 0% stake in Core Laboratories N.V.
05/02/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/27/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/03/2023 4 van Dijken Eeuwijk Monique (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Exercised 5,485 options to buy @ $0
04/03/2023 4 Temeng Kwaku (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Granted 6,419 options to buy @ $0
Exercised 5,485 options to buy @ $0
04/03/2023 4 Straughen Michael (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 2,524 shares @ $22.05, valued at $55.7k
Granted 6,419 options to buy @ $0
Exercised 5,485 options to buy @ $0
04/03/2023 4 Murray Katherine (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Granted 6,419 options to buy @ $0
Exercised 5,485 options to buy @ $0
04/03/2023 4 Klingensmith Harvey Robert (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Granted 6,419 options to buy @ $0
Exercised 5,485 options to buy @ $0
04/03/2023 4 Carnes Martha Z. (Director) has filed a Form 4 on CORE LABORATORIES N V
Txns: Granted 6,419 options to buy @ $0
Exercised 5,485 options to buy @ $0
02/28/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
02/14/2023 SC 13G/A ALGER ASSOCIATES INC reports a 8.3% stake in Core Laboratories N.V.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A EARNEST PARTNERS LLC reports a 7.7% stake in CORE LABORATORIES N.V.
02/03/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/26/2023 SC 13G/A BlackRock Inc. reports a 12.6% stake in CORE LABORATORIES N V
01/20/2023 SC 13G/A BlackRock Inc. reports a 12.6% stake in CORE LABORATORIES N V
01/17/2023 425 Form 425 - Prospectuses and communications, business combinations:
01/17/2023 425 Form 425 - Prospectuses and communications, business combinations:
01/17/2023 8-K Quarterly results
01/04/2023 4 Gresham Gwendolyn (SVP) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 4,722 shares @ $20.27, valued at $95.7k
Exercised 12,000 options to buy @ $0
01/04/2023 4 Hill Christopher Scott (SVP & CFO) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 12,470 shares @ $20.27, valued at $252.8k
Exercised 31,688 options to buy @ $0
01/04/2023 4 Daniels Kevin (CAO & Treasurer) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 2,361 shares @ $20.27, valued at $47.9k
Exercised 6,000 options to buy @ $0
01/04/2023 4 Bruno Lawrence (Chairman and CEO) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 35,892 shares @ $20.27, valued at $727.5k
Exercised 91,212 options to buy @ $0
12/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/04/2022 8-K Quarterly results
10/27/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 8-K Quarterly results
10/03/2022 4 Tattoli Mark Damian (SVP, Gen Counsel & Secretary) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 276 shares @ $13.48, valued at $3.7k
Exercised 700 options to buy @ $0
08/02/2022 4 Tattoli Mark Damian (SVP, Gen Counsel & Secretary) has filed a Form 4 on CORE LABORATORIES N V
Txns: Paid exercise price by delivering 112 shares @ $18.02, valued at $2k
Paid exercise price by delivering 54 shares @ $18.02, valued at $973.1
Exercised 250 options to buy @ $0
Exercised 120 options to buy @ $0
07/28/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/27/2022 8-K Quarterly results
Docs: "CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended % Variance June 30, 2022 June 30, 2021 vs. Q1-22 vs. Q2-21 REVENUE $120,898 $115,300 $118,745 4.9% 1.8% OPERATING EXPENSES: Costs of services and sales 97,957 96,952 93,841 1.0% 4.4% General and administrative expense 6,847 12,545 9,670 % % Depreciation and amortization 4,360 4,557 4,751 % % Other expense, net 82 1,637 % NM Total operating expenses 109,246 115,691 105,945 % 3.1% OPERATING INCOME 11,652 12,800 NM % Interest expense 2,707 2,644 2,530 2.4% 7.0% Income from continuing operations before income tax expense 8,945 10,270 NM % Income tax expense 1,789 2,053 NM % Income from continuing operations 7,156 8,217 NM % Net income 7,156 8,217 NM % Net income attributable to non-control..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy